Can Steroids Make a C. diff Infection Worse?

Corticosteroids can worsen a Clostridioides difficile (C. diff) infection in several measurable ways: they raise the likelihood of getting the infection in the first place, increase the chance it comes back after treatment, and are associated with more severe outcomes including death. The picture is not entirely one-sided, though. A handful of studies have found scenarios where steroid use did not increase risk or even appeared protective, making the relationship between steroids and C. diff more context-dependent than a flat “yes, steroids make it worse.” Understanding when and how steroids become a problem can help you have a more informed conversation with your doctor, especially if you depend on steroids to manage another condition.

Steroids as a Risk Factor for Getting C. diff

A large Swedish population-based study that compared C. diff cases with matched controls found that corticosteroid use more than doubled the odds of developing a C. diff infection, with an adjusted odds ratio of about 2.4.¹ That puts corticosteroids among the stronger non-antibiotic drug risk factors identified in the study, trailing only antidiarrheal medications and sitting ahead of proton-pump inhibitors. The finding makes intuitive sense: steroids dampen the immune system’s ability to fight infections, and C. diff exploits exactly that kind of opening.

A ten-year analysis of inflammatory bowel disease (IBD) patients in South Korea echoed this concern, finding that steroid use for longer than 90 days was significantly associated with developing C. diff.² That detail about duration matters: it suggests the risk may accumulate with extended courses rather than being triggered by a brief burst of prednisone.

Complicating this, one study of hospitalized patients already receiving broad-spectrum antibiotics found the opposite: those who also received corticosteroids actually had lower odds of developing C. diff, by about 46%.³ The researchers also found no dose-response relationship: higher steroid doses and longer courses did not correlate with more infections. This result might reflect the anti-inflammatory properties of steroids calming the gut environment in patients whose intestinal lining was already under assault from aggressive antibiotics. It also underscores that the risk landscape shifts depending on what else is happening in a patient’s body and medication regimen.

Steroids and C. diff Recurrence

Where the evidence gets more consistently alarming is in recurrence. C. diff is notorious for coming back after treatment, and steroids appear to raise that risk substantially. A retrospective study of hospital-onset C. diff infections found that patients who received corticosteroids during their acute infection had a recurrence rate of about 14%, compared to roughly 2% in those who did not.⁴ Among patients who had never been exposed to steroids before, the gap was even wider: a third of those given corticosteroids during the acute infection experienced a recurrence, versus about 5% in the no-steroid group.

A separate analysis of over 2,000 hospitalized patients identified steroids as a significant independent risk factor for recurrent C. diff, with steroid users roughly 65% more likely to see the infection return.⁵ That study placed steroid use alongside proton-pump inhibitor use and end-stage kidney disease as the major recurrence risk factors.

One interesting wrinkle comes from a study that split older adults into two groups: community-dwelling and nursing home residents. For people living in the community, corticosteroid exposure was actually associated with about a 39% lower risk of recurrence. But for nursing home residents, corticosteroid exposure raised the risk nearly sixfold.⁶ The stark difference likely reflects the overall health and immune status of each group: nursing home residents tend to be frailer, have more coexisting illnesses, and face more ongoing antibiotic exposure, all of which compound the immunosuppressive effects of steroids. The takeaway is that the same drug can behave very differently depending on who is taking it.

Links to Severe Disease and Death

Beyond raising the odds of initial infection and recurrence, steroid use has been tied to the most feared outcomes of C. diff: fulminant colitis and death. A study specifically examining predictors of fatal C. diff colitis found that steroid use was significantly associated with mortality, alongside markers of acute illness like organ dysfunction and signs of sepsis.⁷ The study also flagged toxic megacolon, a life-threatening complication where the colon stops functioning and balloons dangerously, as a mortality-associated finding. Steroids may contribute to this complication by masking early warning signs of worsening infection: they suppress fever, lower the white blood cell count, and reduce abdominal pain, all signals that clinicians rely on to escalate care.

Animal research has added a mechanistic layer to these clinical observations. In a mouse model, the corticosteroid budesonide dramatically worsened C. diff colitis when given alongside the infection. Mortality rates reached as high as 90% in some treatment groups, and even low doses of budesonide combined with the C. diff antibiotic fidaxomicin produced worse outcomes than the antibiotic alone.⁸ Mouse studies do not translate directly to humans, but this work reinforces the concern that dampening inflammation in the gut during an active C. diff infection can backfire.

Why Steroids and C. diff Are a Dangerous Combination

C. diff damages the colon primarily through toxins that trigger an intense inflammatory response. That inflammation is a double-edged sword: it recruits immune cells to fight the infection but also causes the diarrhea, tissue damage, and potentially life-threatening complications that make C. diff so dangerous.⁹ The body’s adaptive immune system eventually steps in to control the infection, and antibodies against C. diff toxins are one of the key defenses against recurrence.

Corticosteroids interfere with multiple steps in this process. They broadly suppress both the innate immune response (the rapid first wave of defense) and the adaptive immune response (the slower, more targeted defense that builds lasting protection). By blunting the immune reaction, steroids may allow C. diff to persist longer, produce more toxin, and gain a deeper foothold in the gut lining. This also helps explain why steroids are so strongly linked to recurrence: if the adaptive immune response never fully mounts, the body fails to build adequate defenses, and the infection returns once antibiotics are stopped.

Steroids also appear to alter the gut’s microbial community. A review of studies on immunosuppressive drugs in organ transplant recipients found that agents including prednisone were associated with shifts in key bacterial populations. Quantities of beneficial anaerobic bacteria from families like Ruminococcaceae and Lachnospiraceae decreased, while potentially harmful species gained ground.¹⁰ A healthy diversity of gut bacteria is one of the main barriers preventing C. diff from establishing itself in the colon, so anything that disrupts that community creates an opening for infection.

Navigating Steroids When You Have Inflammatory Bowel Disease

The steroid-C. diff dilemma is most acute for people with IBD, including Crohn’s disease and ulcerative colitis. These patients face a cruel double bind: steroids are a mainstay treatment for IBD flares, but IBD itself already raises the risk of C. diff, and steroid use adds another layer of vulnerability on top. The South Korean database study found that steroids, immunomodulators, and biologics were all independently associated with higher C. diff rates in IBD patients, with steroid courses exceeding 90 days posing a particularly elevated risk.²

Making things harder, an IBD flare can look almost identical to a C. diff infection: both cause diarrhea, abdominal cramping, and bloody stools. If a doctor mistakes a C. diff infection for an IBD flare and prescribes steroids to calm it down, the result can be a worsening infection that spirals. This is why testing for C. diff is considered standard practice before escalating immunosuppression in any IBD patient presenting with new or worsening diarrhea.

Current clinical guidance recommends postponing any escalation of steroids during an acute C. diff episode until appropriate antibiotic therapy for C. diff has been started, typically waiting at least 72 to 96 hours.¹¹ Beyond that window, the guidance becomes less definitive. Most expert recommendations suggest maintaining existing immunosuppressive therapy, including ongoing steroid doses, rather than abruptly stopping it, because suddenly withdrawing steroids can trigger an IBD flare that further destabilizes the patient.¹² The decision to withhold, continue, or escalate steroids is treated as an individualized judgment call, because the evidence base is not strong enough to dictate a blanket rule.

Other Medications That Compound the Risk

Steroids rarely act alone. Most people taking corticosteroids are also on other medications, and several of those drugs independently raise C. diff risk. The Swedish population study is useful here because it quantified the odds for a range of common drug classes. Proton-pump inhibitors, the widely prescribed acid-suppressing drugs, raised C. diff odds by roughly 80%. Antidepressants, constipation drugs, and histamine H2-receptor antagonists also showed increased risk. Antidiarrheals were the strongest non-antibiotic risk factor by a wide margin, with more than seven times the odds of C. diff.¹

On the protective side, lipid-modifying drugs like statins and aspirin were each associated with about a 20% reduction in C. diff odds. Nonsteroidal anti-inflammatory drugs showed no significant association in either direction, which is worth knowing if you are weighing pain management options while on steroids.

The practical relevance is that if you are taking corticosteroids along with a proton-pump inhibitor, you are stacking two independent risk factors for C. diff. A study of hospitalized patients found that both drugs were individually significant predictors of recurrence, and the combination is common in clinical practice.⁵ If your proton-pump inhibitor was started casually and you are at elevated C. diff risk, it may be worth asking your doctor whether you still need it.

Why the Evidence Sometimes Points in Different Directions

If you have been reading closely, you may have noticed the studies do not all agree. One shows steroids doubling the odds of C. diff, another shows them cutting the odds nearly in half. Community-dwelling elderly seem protected, nursing home residents face amplified danger. These contradictions are not a sign that the science is broken. They reflect how heavily context matters.

The patients in the study that found a protective effect were already receiving broad-spectrum antibiotics in a hospital setting.³ In that specific scenario, the antibiotics were already hammering the gut microbiome, and the dominant driver of C. diff risk was the antibiotic exposure itself. Steroids might have reduced gut inflammation enough to help maintain the intestinal barrier, or the comparison group (patients sick enough to need aggressive antibiotics but not sick enough to need steroids) might have had other unmeasured risk factors. Either way, this finding applies to a narrow clinical window and should not be generalized to suggest that steroids are protective against C. diff overall.

Similarly, the finding that community-dwelling older adults on steroids had fewer recurrences likely reflects the fact that these were relatively healthier individuals managing conditions like asthma or arthritis, not critically ill patients in intensive care.⁶ Their baseline immune function, nutritional status, and microbial diversity were all likely stronger, providing a buffer that nursing home residents did not have. The lesson is that steroids do not carry the same C. diff risk for everyone; the sicker and more immunocompromised you already are, the more dangerous steroids become in this context.

What to Watch for If You Are on Steroids

If you are taking corticosteroids and develop watery diarrhea, especially more than three loose stools in a day, it is worth getting tested for C. diff rather than assuming the diarrhea is a side effect of your medication or an unrelated stomach bug. This is particularly true if you have recently taken antibiotics, are hospitalized, or have been on steroids for more than a few weeks. C. diff diarrhea often has a distinctive foul odor, and it can be accompanied by fever, abdominal pain, and loss of appetite, though steroids may blunt some of these symptoms and make the infection harder to recognize early.

Stopping steroids abruptly on your own because you are worried about C. diff risk is not advisable, especially if you have been on them for more than a week or two. Abrupt withdrawal can cause adrenal insufficiency, a potentially dangerous condition where your body cannot produce enough cortisol on its own. Any changes to your steroid regimen should be discussed with your doctor, who can weigh the C. diff risk against the condition the steroids are treating and taper the dose safely if appropriate.

Good hygiene practices matter more when you are immunosuppressed. C. diff spreads through spores that are resistant to alcohol-based hand sanitizers, so washing your hands with soap and water after using the bathroom and before eating is the most effective prevention strategy. If you are visiting or staying in a healthcare facility, do not hesitate to ask staff whether they have washed their hands before touching you. These measures are standard infection-control advice, but they carry extra weight when your immune system is already operating at reduced capacity.

1
Gut. Commonly prescribed drugs as risk factors for Clostridioides difficile infections: a Swedish population-based case–control study
2
Journal of Korean Medical Science. The Prevalence and Risk Factors of Clostridioides difficile Infection in Inflammatory Bowel Disease
3
PubMed Central. Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use
4
PubMed Central. Impacts of Corticosteroid Therapy at Acute Stage of Hospital-Onset Clostridioides difficile Infections
5
PubMed. Factors Predicting Recurrence of Clostridium difficile Infection (CDI) in Hospitalized Patients: Retrospective Study of More Than 2000 Patients
6
PubMed. Medication Exposure and Risk of Recurrent Clostridium difficile Infection in Community-Dwelling Older People and Nursing Home Residents
7
PubMed. C. difficile colitis–predictors of fatal outcome
8
PubMed. Budesonide, an anti-inflammatory drug, exacerbate clostridioides difficile colitis in mice
9
PubMed. Immune responses induced by Clostridium difficile
10
Transplant Infectious Disease. The alteration of the gut microbiome by immunosuppressive agents used in solid organ transplantation
11
PubMed Central. Management of inflammatory bowel disease with Clostridium difficile infection
12
Clinical Gastroenterology and Hepatology. Management of Clostridium difficile infection in inflammatory bowel disease (IBD)